ArticleCureus2026
Immunotherapy-Induced Glutamic Acid Decarboxylase 65 Cerebellitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are an important treatment modality for advanced cancer. However, they carry the risk of immune-related adverse events (irAEs) secondary to their mechanism of action. ICI medications function by inhibiting the checkpoints that suppress immune cells, which exist to prevent autoimmunity, and prime these cells to attack and eliminate cancer. While ICIs have substantially improved the prognosis for patients with advanced cancer, some patients experience adverse effects from this autoimmune state. One less common, but potentially life-threatening toxicity is cerebellitis. We present a case of anti-glutamic acid decarboxylase 65 (anti-GAD 65) related ICI cerebellitis in a patient with uterine carcinosarcoma on dostarlimab. This patient presented with nonspecific symptoms, including fatigue and a concerning symptom of ataxia. Full neurological evaluation demonstrated anti-GAD 65 antibodies in both her serum and cerebrospinal fluid (CSF). She was unable to start outpatient treatment and was admitted for intravenous steroids and intravenous immunoglobulin (IVIG) with subsequent improvement in her symptoms. She was placed on a prolonged steroid taper with regular IVIG infusions. Her immunotherapy was discontinued. This case report highlights the importance of early clinical suspicion of ICI-related neurotoxicities and rapid treatment initiation. Prompt recognition and early intervention are important to minimize long-term disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.